The levels of two protein biomarkers, GFAP and UCH-L1 found in blood samples taken 24 hours after a traumatic brain injury can help to predict which patients will die and which will obtain a severe disability.
A newly developed immuno-infrared sensor allowed researchers to discover biomarkers for Alzheimer's disease in blood samples 17 years before clinical symptoms appeared. The sensory is able to detect the misfolding of amyloid beta.
Researchers have identified a blood biomarker that predicts the risk of suicide in patients with major depressive disorder. The biomarker also can help researchers understand the molecular changes in suicide victims.
The discovery of a unique ratio of metabolites in blood samples taken from early-stage Alzheimer's patients could be a critical new biomarker for early detection of the neurodegenerative disease.
NfL, a single biomarker in the blood, can accurately predict the presence of underlying neurodegenerative disorders, such as FTD and ALS, in people with cognitive problems.
A new blood test can distinguish the severity of a person's depression and their risk for developing severe depression at a later point. The test can also determine if a person is at risk for developing bipolar disorder. Researchers say the blood test can also assist in tailoring individual options for therapeutic interventions.
Blood samples taken from people enrolled in an Alzheimer's research study revealed higher levels of phosphorylated tau 217 that correlated with the presence of amyloid plaques. People with amyloid in their brains had up to three times more of the tau protein in their blood than those who had no evidence of amyloid accumulation. The higher levels of the protein were evident even in people with no signs of cognitive decline.
New evidence confirms COVID-19 infection is the cause of the Kawasaki-like syndrome affecting children.
Six proteins in the blood can be used to assess a person's risk of developing cerebral small vessel disease (CSVD). CSVD has been linked to an increased risk of stroke and Alzheimer's disease.
Combining artificial intelligence technology and blood samples, researchers were able to predict and explain the progression of Alzheimer's and Huntington's disease. The new algorithm was able to detect alterations in gene expression over decades from patients' blood samples.
Novel biomarkers for glioblastoma brain cancer have been identified in bodily fluids. The discovery may lead to a new, simple, non-invasive blood test to detect brain cancer in the future.
Researchers have identified two new species of bacteria in the blood of patients in China. The bacterias are in the Enterobacter genus and are resistant to multiple antibiotics. Enterobacter has previously been linked to meningitis and other serious medical conditions.
